Related Experiment Video

Updated: Sep 12, 2025

High-Throughput Cardiotoxicity Screening Using Mature Human Induced Pluripotent Stem Cell-Derived Cardiomyocyte Monolayers
14:03

High-Throughput Cardiotoxicity Screening Using Mature Human Induced Pluripotent Stem Cell-Derived Cardiomyocyte Monolayers

Published on: March 24, 2023

2.0K

Cardiac Adverse Events Associated With Elotuzumab: A Disproportionality Analysis Using FDA Adverse Event Reporting

Muhammed Favas K T, Beema T Yoosuf, Dipika Bansal

    The Annals of Pharmacotherapy
    |August 4, 2025
    PubMed
    Abstract

    No abstract available in PubMed .

    More Related Videos

    Hybrid Cell Analysis System to Assess Structural and Contractile Changes of Human iPSC-Derived Cardiomyocytes for Preclinical Cardiac Risk Evaluation08:03

    Hybrid Cell Analysis System to Assess Structural and Contractile Changes of Human iPSC-Derived Cardiomyocytes for Preclinical Cardiac Risk Evaluation

    Published on: October 20, 2022

    1.9K
    Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography09:34

    Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography

    Published on: February 17, 2022

    3.5K

    Related Concept Videos

    Pharmacovigilance01:19

    Pharmacovigilance

    Post-marketing surveillance is a critical component of pharmaceutical regulation, often uncovering unanticipated adverse drug reactions (ADRs) once a drug is widely used over an extended period.
    This process, termed pharmacovigilance, aims to detect, evaluate, and minimize harmful effects related to medication use. The data collection for pharmacovigilance depends on spontaneous reporting systems, where healthcare professionals or patients voluntarily report suspected ADRs.
    In some cases, there...
    993
    Hazard Ratio01:12

    Hazard Ratio

    The hazard ratio (HR) is a widely used measure in clinical trials to compare the risk of events, such as death or disease recurrence, between two groups over time. It reflects the ratio of hazard rates—the instantaneous risk of the event occurring—between a treatment group and a control group. This measure provides valuable insights into the relative effectiveness of a treatment by assessing how the risk of an event differs between the two groups.
    For example, in a clinical trial...
    247